Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Neurochem Res ; 48(12): 3571-3584, 2023 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-37556038

RESUMEN

Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative disease with selective degeneration of motor neurons. It has been reported that an increase in the levels of inflammatory cytokines and glial cells such as reactive astrocytes is closely involved in the pathological progression of ALS. Recently, the levels of neuropathic cytotoxic (A1) astrocytes among reactive astrocytes have reportedly increased in the central nervous system of ALS mice, which induce motor neuron degeneration through the production of inflammatory cytokines and secretion of neuropathic factors. Hence, elucidating the induction mechanism of A1 astrocytes in ALS is important to understand the mechanism of disease progression in ALS. In this study, we observed that the expression of peroxiredoxin 6 (PRDX6), a member of the peroxiredoxin family, was markedly upregulated in astrocytes of the lumbar spinal cord of SOD1G93A mice model for ALS. Additionally, when PRDX6 was transiently transfected into the mouse astrocyte cell line C8-D1A and human astrocytoma cell line U-251 MG, the mRNA expression of complement C3 (a marker for A1 astrocyte phenotype) and inflammatory cytokines was increased. Furthermore, the mRNA expression of C3 and inflammatory cytokine was increased in C8-D1A and U-251 MG cells stably expressing PRDX6, and the increased mRNA expression was significantly suppressed by MJ33 (lithium[1-hexadecoxy-3-(2,2,2-trifluoroethoxy) propan-2-yl] methyl phosphate), an inhibitor of the phospholipase A2 activity of PRDX6. Our results suggest that the expression of PRDX6 in astrocytes plays an important role in the induction of A1 astrocytes and expression of inflammatory cytokines in the ALS mice model.


Asunto(s)
Esclerosis Amiotrófica Lateral , Enfermedades Neurodegenerativas , Síndromes de Neurotoxicidad , Ratones , Humanos , Animales , Esclerosis Amiotrófica Lateral/metabolismo , Astrocitos/metabolismo , Peroxiredoxina VI/genética , Peroxiredoxina VI/metabolismo , Enfermedades Neurodegenerativas/metabolismo , Ratones Transgénicos , Médula Espinal/metabolismo , Citocinas/metabolismo , Modelos Animales de Enfermedad , Síndromes de Neurotoxicidad/metabolismo , ARN Mensajero/metabolismo , Superóxido Dismutasa-1/genética , Superóxido Dismutasa/metabolismo
2.
J Obstet Gynaecol Res ; 49(7): 1684-1688, 2023 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-37016489

RESUMEN

As 2 years have passed since the outbreak of coronavirus disease 2019 (COVID-19), we had an examination of the measures taken at the perinatal medical and child centers during this period at 42 National University Hospital. The first questionnaire survey was conducted during March 17-25, 2022 and the second questionnaire survey was conducted during April 4-30, 2022. For the treatment of pregnant women with COVID-19, a public health center-coordinated triage system had been created and implemented in each region and prefecture. The issues related to the hospital management of pregnant women with COVID-19 include the hindrances to the normal functioning of the center, the limited number of hospital beds and medical care systems as the beds were dedicated to patients with COVID-19, and the problems associated with the mode of delivery. There were no set rules regarding the management of mothers and babies at delivery and thereafter. Initially, cesarean delivery was allowed in almost all cases to reduce the risk of exposure to medical staff. Furthermore, many institutions did not permit expressed breast milk feeding and direct breastfeeding during the quarantine period. The COVID-19 pandemic has been created a shortage of healthcare delivery systems. It is expected that the emergence of new infectious diseases and pandemics will cause the same pressure on systems providing healthcare in the future.


Asunto(s)
COVID-19 , Complicaciones Infecciosas del Embarazo , Femenino , Humanos , Embarazo , Hospitales , Pandemias , Complicaciones Infecciosas del Embarazo/terapia , Mujeres Embarazadas , SARS-CoV-2 , Recién Nacido
3.
J Reprod Immunol ; 138: 103099, 2020 04.
Artículo en Inglés | MEDLINE | ID: mdl-32050141

RESUMEN

Immunohistochemical localisation of indoleamine 2,3-dioxygenase was studied in order to better understand the pathophysiology of placenta accreta spectrum. In the decidua staining for indoleamine 2,3-dioxygenase was found in the glandular epithelium with some additional positive cells. Extravillous cytotrophoblast invasion was present in the myometrium which was not covered by the decidual tissue whereas myometrial invasion of cytotrophoblasts was absent where this tissue lay deep to decidua. These results suggest that indoleamine 2,3-dioxygenase expression in the decidua may normally control trophoblast invasion and absence of its expression where decidua is absent may be involved in the pathogenesis of the over-invaded placenta.


Asunto(s)
Cesárea/efectos adversos , Cicatriz/patología , Decidua/patología , Indolamina-Pirrol 2,3,-Dioxigenasa/metabolismo , Placenta Accreta/etiología , Cicatriz/etiología , Decidua/cirugía , Femenino , Humanos , Histerectomía , Indolamina-Pirrol 2,3,-Dioxigenasa/análisis , Placenta Accreta/patología , Placenta Accreta/cirugía , Embarazo , Primer Trimestre del Embarazo , Trofoblastos/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...